| PD-L1 expression as a predictive biomarker in cancer immunotherapy SP Patel, R Kurzrock Molecular cancer therapeutics 14 (4), 847-856, 2015 | 2376 | 2015 |
| Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers AM Goodman, S Kato, L Bazhenova, SP Patel, GM Frampton, V Miller, ... Molecular cancer therapeutics 16 (11), 2598-2608, 2017 | 2236 | 2017 |
| The biology of chronic myeloid leukemia S Faderl, M Talpaz, Z Estrov, S O'Brien, R Kurzrock, HM Kantarjian New England Journal of Medicine 341 (3), 164-172, 1999 | 1904 | 1999 |
| Phase II trial of curcumin in patients with advanced pancreatic cancer N Dhillon, BB Aggarwal, RA Newman, RA Wolff, AB Kunnumakkara, ... Clinical cancer research 14 (14), 4491-4499, 2008 | 1628 | 2008 |
| The molecular genetics of Philadelphia chromosome–positive leukemias R Kurzrock, JU Gutterman, M Talpaz New England Journal of Medicine 319 (15), 990-998, 1988 | 1182 | 1988 |
| Epstein-Barr virus and cancer MP Thompson, R Kurzrock Clinical cancer research 10 (3), 803-821, 2004 | 1098 | 2004 |
| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial GS Falchook, GV Long, R Kurzrock, KB Kim, TH Arkenau, MP Brown, ... The Lancet 379 (9829), 1893-1901, 2012 | 1053 | 2012 |
| Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors N Krishnamurthy, R Kurzrock Cancer treatment reviews 62, 50-60, 2018 | 1026 | 2018 |
| Autophagy as a target for anticancer therapy F Janku, DJ McConkey, DS Hong, R Kurzrock Nature reviews Clinical oncology 8 (9), 528-539, 2011 | 925 | 2011 |
| Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate S Kato, A Goodman, V Walavalkar, DA Barkauskas, A Sharabi, ... Clinical Cancer Research 23 (15), 4242-4250, 2017 | 898 | 2017 |
| The challenges of tumor mutational burden as an immunotherapy biomarker DL Jardim, A Goodman, D de Melo Gagliato, R Kurzrock Cancer cell 39 (2), 154-173, 2021 | 852 | 2021 |
| Liposome‐encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis L Li, FS Braiteh, R Kurzrock Cancer: Interdisciplinary international journal of the American cancer …, 2005 | 814 | 2005 |
| The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing T Helsten, S Elkin, E Arthur, BN Tomson, J Carter, R Kurzrock Clinical cancer research 22 (1), 259-267, 2016 | 792 | 2016 |
| Clinical toxicity of interferons in cancer patients: a review. JR Quesada, M Talpaz, A Rios, R Kurzrock, JU Gutterman Journal of Clinical Oncology 4 (2), 234-243, 1986 | 782 | 1986 |
| Chronic myelogenous leukemia: a concise update HM Kantarjian, A Deisseroth, R Kurzrock, Z Estrov, M Talpaz Blood 82 (3), 691-703, 1993 | 656 | 1993 |
| Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer R Kurzrock, SI Sherman, DW Ball, AA Forastiere, RB Cohen, R Mehra, ... Journal of Clinical Oncology 29 (19), 2660-2666, 2011 | 643 | 2011 |
| Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study JK Sicklick, S Kato, R Okamura, M Schwaederle, ME Hahn, CB Williams, ... Nature medicine 25 (5), 744-750, 2019 | 641 | 2019 |
| Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial GS Falchook, KD Lewis, JR Infante, MS Gordon, NJ Vogelzang, ... The lancet oncology 13 (8), 782-789, 2012 | 618 | 2012 |
| Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative AM Tsimberidou, NG Iskander, DS Hong, JJ Wheler, GS Falchook, S Fu, ... Clinical cancer research 18 (22), 6373-6383, 2012 | 609 | 2012 |
| Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial JR Infante, LA Fecher, GS Falchook, S Nallapareddy, MS Gordon, ... The lancet oncology 13 (8), 773-781, 2012 | 608 | 2012 |
